Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 4 min read

How does tau pathology work?

Tau pathology refers to the abnormal phosphorylation and aggregation of the microtubule-associated protein tau, leading to neurofibrillary tangles and neurodegeneration. This page outlines the molecular mechanisms, resea

peptides-pro Editorial

Tau pathology is the term for the abnormal hyperphosphorylation and aggregation of the microtubule-associated protein tau, which forms neurofibrillary tangles (NFTs) in neurons. Tau is a member of the microtubule-associated protein family, and its dysfunction is a hallmark of Alzheimer's disease (AD) and other tauopathies, including frontotemporal lobar degeneration (FTLD), corticobasal degeneration syndrome (CBS), and progressive supranuclear palsy (PSP) [2][4]. The human MAPT gene encodes tau, which exists as six isoforms; however, the EVIDENCE block does not provide sequence, formula, or molecular weight details.

The work centres on the tau pathway, specifically the role of tau hyperphosphorylation and aggregation in driving synaptic dysfunction and neurodegeneration, as well as the cholinergic deficits and neuroinflammation that accompany these processes [2].

Research Studies

Natural medicines and tau hyperphosphorylation in Alzheimer's disease models

A bibliometric analysis and narrative review of natural medicines for AD mapped research trends from 2001 to 2025 and examined mechanistic evidence from original experimental studies [1]. The review reported that natural medicines have been widely investigated for AD, with a focus on pathways including tau hyperphosphorylation, oxidative stress, and neuroinflammation. The findings were derived from in vitro and in vivo studies, and the review noted that the relationship between bibliometric themes and experimental evidence remains insufficiently characterized [1].

Medicinal plants and tau-related mechanisms in preclinical and clinical studies

A comprehensive review synthesized evidence from in vitro, in vivo, and clinical studies on 15 medicinal plants and 21 active compounds with relevance to AD [2]. The review identified that AD is driven by amyloid-β accumulation, tau hyperphosphorylation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and cholinergic deficits. Studies were included if they reported neuroprotective activity in at least one AD-related pathway. The review concluded that current FDA-approved therapies provide only modest symptomatic relief, underscoring the need for multi-targeted alternatives [2].

Targeted neuronal reprogramming and tauopathy in the P301S mouse model

A study investigated whether targeted and intermittent expression of Yamanaka factors (YFs) in hippocampal neurons restores cognitive function and neural network integrity in the P301S mouse model of tauopathy [3]. The researchers first showed that controlled YFs expression in hippocampal neurons increases excitatory synaptic transmission and neural synchrony. The study reported that this intervention rescued memory and neural synchrony in the P301S mice. These findings are animal-only and have not been confirmed in human studies [3].

Davunetide (AL-108) and predicted tauopathies in a pilot clinical study

A pilot clinical study (NCT01056965) evaluated davunetide (NAP, AL-108) in patients with predicted tauopathies, including FTLD with predicted tau pathology, CBS, and PSP [4]. The primary objective was to obtain preliminary safety and tolerability data. Secondary objectives included short-term changes at 12 weeks in clinical, functional, and biomarker measurements from baseline, including cerebrospinal fluid (CSF) tau levels, eye movements, and brain MRI measurements. The study was designed to assess safety and tolerability, not efficacy [4].

NAD+-mitophagy axis and neurodegeneration in aging models

A combined artificial intelligence and wet-lab approach identified a pivotal role of the NAD+-mitophagy axis in aging and neurodegeneration [5]. The study hypothesized that age-dependent impairment of this axis contributes to brain aging and neurodegeneration. The findings are from preclinical models and are marked as reference only; they support the broader context of tau pathology research but are not the primary focus of this page [5].

Biochemical modulators of synaptic plasticity in Alzheimer's disease

A review of biochemical modulators of synaptic plasticity provided an integrative overview of the molecular and biochemical factors governing synaptic plasticity and their disruption in AD [6]. The review discussed how synaptic dysfunction is the earliest and most critical pathological feature of AD, directly contributing to cognitive decline. This evidence is marked as reference only and supports the understanding of tau pathology's impact on synaptic function [6].

Comparison of tau pathology models and study designs

Study Model / Population Key Focus Evidence Type
Bibliometric analysis [1] In vitro and in vivo studies Natural medicines and tau hyperphosphorylation Review
Medicinal plants review [2] In vitro, in vivo, and clinical studies 15 plants, 21 compounds, tau-related pathways Review
Neuronal reprogramming [3] P301S mouse model of tauopathy Yamanaka factors, memory, neural synchrony Animal-only
Davunetide pilot [4] Patients with FTLD, CBS, or PSP Safety, tolerability, CSF tau levels Clinical (pilot)
NAD+-mitophagy axis [5] Preclinical models Aging and neurodegeneration Reference only
Synaptic plasticity review [6] Not specified Biochemical modulators of synaptic plasticity Reference only

If you are reading this for personal health reasons

The materials and compounds discussed on this page are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp